dacomitinib
Ligand Summary
Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations.
UNII: 2XJX250C20
PubChem: 11511120
PubChem: 70693519
Guide to Pharmacology: 7422
ChEMBL: CHEMBL2110732
ChEMBL: CHEMBL2105719
DrugCentral: 5297
LyCHI: PSP3LBW32FKK
Target Activities
20 Activities
Items per page:
1 – 10 of 20
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Kd | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||